Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Nina Lamers-Kok, Monica Raimo(University of Turin), Didem Özkazanç(Hacettepe University Hospital), Adil Doganay Duru(Karolinska University Hospital), Denise Panella, Lucia Kučerová(Cancer Research Institute of the Slovak Academy of Sciences), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Haiping Liu(Chinese PLA General Hospital), Anna‐Maria Georgoudaki
Cited by 178
Related Papers
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
|PLoS ONE|2011|239
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
|Clinical Cancer Research|2017|211
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
|Frontiers in Immunology|2017|197